Cargando…

A Novel Approach to Delayed-Start Analyses for Demonstrating Disease-Modifying Effects in Alzheimer’s Disease

One method for demonstrating disease modification is a delayed-start design, consisting of a placebo-controlled period followed by a delayed-start period wherein all patients receive active treatment. To address methodological issues in previous delayed-start approaches, we propose a new method that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu-Seifert, Hong, Andersen, Scott W., Lipkovich, Ilya, Holdridge, Karen C., Siemers, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363486/ https://www.ncbi.nlm.nih.gov/pubmed/25781335 http://dx.doi.org/10.1371/journal.pone.0119632

Ejemplares similares

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Correction: A Novel Approach to Delayed-Start Analyses for Demonstrating Disease-Modifying Effects in Alzheimer’s Disease
Publicado: (2015)

Function and clinical meaningfulness of treatments for mild Alzheimer's disease
por: Siemers, Eric, et al.
Publicado: (2016)

Delayed-start analysis for demonstrating disease modification of solanezumab
por: Wolters, Frank J., et al.
Publicado: (2015)

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
por: Willis, Brian A., et al.
Publicado: (2018)

Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model
por: Furiak, Nicolas M, et al.
Publicado: (2010)

Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Assessing quality of life in Alzheimer's disease: Implications for clinical trials
por: Kahle-Wrobleski, Kristin, et al.
Publicado: (2016)

Therapeutic Approaches to Delay the Onset of Alzheimer's Disease
por: Kumar, Raj, et al.
Publicado: (2011)

It All Starts at the Ends: Multifaceted Involvement of C- and N-Terminally Modified Cholinesterases in Alzheimer’s Disease
por: Berson, Amit, et al.
Publicado: (2010)

Amyloid-ß-directed immunotherapy for Alzheimer's disease
por: Lannfelt, L, et al.
Publicado: (2014)

Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease
por: Ettcheto, Miren, et al.
Publicado: (2019)

ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
por: Krafft, Grant A., et al.
Publicado: (2022)

Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia
por: Svaldi, Diana Otero, et al.
Publicado: (2022)

Identifying patterns in treatment response profiles in acute bipolar mania: a cluster analysis approach
por: Lipkovich, Ilya A, et al.
Publicado: (2008)

Effects of the Medicare Alzheimer's Disease Demonstration on Medicare Expenditures
por: Newcomer, Robert, et al.
Publicado: (1999)

Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease
por: Carlson, Christopher, et al.
Publicado: (2016)

Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic
por: Qu, Yongming, et al.
Publicado: (2021)

When Does Alzheimer′s Disease Really Start? The Role of Biomarkers
por: Lloret, Ana, et al.
Publicado: (2019)

Disease-modifying drugs in Alzheimer’s disease
por: Ghezzi, Laura, et al.
Publicado: (2013)

Disease-modifying treatments in Alzheimer’s disease
por: Edwards, Marc, et al.
Publicado: (2023)

Derivation of cutoffs for the Elecsys(®) amyloid β (1–42) assay in Alzheimer's disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

Caregiver Supports: Outcomes From the Medicare Alzheimer's Disease Demonstration
por: Yordi, Cathleen, et al.
Publicado: (1997)

Start-Up of the Colorectal Cancer Screening Demonstration Program
por: DeGroff, Amy, et al.
Publicado: (2008)

Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma
por: Gottlow, Mattis, et al.
Publicado: (2019)

Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer’s Disease
por: Ono, Kenjiro, et al.
Publicado: (2020)

Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease
por: Schwarz, Adam J., et al.
Publicado: (2019)

Delay of cognitive gamma responses in Alzheimer's disease
por: Başar, Erol, et al.
Publicado: (2016)

Alzheimer's disease can be treated: Why the delay?
por: Goldsmith, Harry S.
Publicado: (2017)

A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease
por: Portelius, Erik, et al.
Publicado: (2010)

Disease-Modifying Therapy for Transthyretin Amyloidosis: Where to Start? Where to Stop?
por: Fine, Nowell M.
Publicado: (2020)

The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial
por: Burns, Daniel K., et al.
Publicado: (2019)

Who will benefit from antidepressants in the acute treatment of bipolar depression? A reanalysis of the STEP-BD study by Sachs et al. 2007, using Q-learning
por: Wu, Fan, et al.
Publicado: (2015)

A Great Start, but the Long-Term Durability Remains to be Demonstrated
por: Choi, Donghoon
Publicado: (2017)

Differential Network Analyses of Alzheimer's Disease Identify Early Events in Alzheimer's Disease Pathology
por: Xia, Jing, et al.
Publicado: (2014)

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
por: Schapira, Anthony HV, et al.
Publicado: (2013)

Modifiable Risk Factors for Alzheimer’s Disease
por: Edwards III, George A., et al.
Publicado: (2019)

Familial Alzheimer’s Disease and Recessive Modifiers
por: Vélez, Jorge I., et al.
Publicado: (2019)

Update on Disease-Modifying/Preventive Therapies in Alzheimer’s Disease
por: Apter, Jeffrey T., et al.
Publicado: (2015)

Bilingualism as a strategy to delay the onset of Alzheimer’s disease
por: Klimova, Blanka, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4kod6cm97lgsa39ade9moqrtgn